The indications for pharmacogenomic testing are listed by drug.
For each drug, the website identifies the strength of the indication for pharmacogenomic testing. The four strengths of indication are as follows:
Recommended: Pharmacogenomic testing is recommended in the specified clinical setting, ideally before exposure to the drug. Evidence shows that adverse effects can be severe or life-threatening, or that therapeutic failure can cause significant patient harm. International regulatory agencies or key professional organisations recommend testing.
Consider: Pharmacogenomic testing could be considered in the specified clinical setting. Evidence suggests that the risk of adverse effects or therapeutic failure is significant. International regulatory agencies or key professional organisations generally recommend testing.
Available: Pharmacogenomic testing is available. Evidence suggests an association with adverse effects or therapeutic failure. There is no consensus from international regulatory agencies and key organisations regarding testing.
No indication identified: Although a pharmacogenomic test may be available, a search of international regulatory agencies and key organisations yielded no recommendations for pharmacogenomic testing.
Additionally, each entry includes:
- Rationale for pharmacogenomic testing
- Prevalence of relevant gene variants (where available)
- A link to the associated CPIC® guidance
- Links to further information
- Availability of the pharmacogenomic test in Australia
- The availability of a Medicare rebate for the test specified.